# Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

> **NCT02064491** · PHASE2 · COMPLETED · sponsor: **Finnish Lung Cancer Group** · enrollment: 18 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT02064491
- **Lead sponsor:** Finnish Lung Cancer Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-12-31
- **Final completion:** 2017-05-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02064491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02064491, "Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02064491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*